Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.
about
Current Trends of Renal Impairment in Multiple MyelomaLooking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
P2860
Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Bortezomib, dexamethasone plus ...... h or without renal impairment.
@ast
Bortezomib, dexamethasone plus ...... h or without renal impairment.
@en
type
label
Bortezomib, dexamethasone plus ...... h or without renal impairment.
@ast
Bortezomib, dexamethasone plus ...... h or without renal impairment.
@en
prefLabel
Bortezomib, dexamethasone plus ...... h or without renal impairment.
@ast
Bortezomib, dexamethasone plus ...... h or without renal impairment.
@en
P2093
P2860
P1476
Bortezomib, dexamethasone plus ...... h or without renal impairment.
@en
P2093
Guangzhong Yang
Wenming Chen
P2860
P304
P356
10.3978/J.ISSN.1000-9604.2013.03.07
P577
2013-04-01T00:00:00Z